Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

RVMDBullishCorporate Developmentsnews

Medium materiality6/10

RVMD Initiates Phase 3 RAS Doublet in PDAC; potential long-term upside

Oct 5, 2026, 8:20 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Phase 3 initiation of a novel RAS(ON) doublet is a meaningful near-term milestone that could re-rate RVMD on pipeline potential; however, success depends on future readouts and data density. Historically, Phase 3 starts have driven volatility but require data to sustain a valuation uplift.

AI summary

What happened, with direct paths to the underlying reporting

Revolution Medicines announced the start of RASolute 309, a global Phase 3 trial of RASONQUE plus zoldonrasib for first-line metastatic PDAC with the G12D mutation. The study compares the doublet against gemcitabine and nab-paclitaxel, with progression-free and overall survival as primary endpoints. Positive results could broaden RVMD's RAS(ON) program and potentially lift long-term value.

RVMD launches Phase 3 RASolute 309 for first-line metastatic PDAC.
Trial tests RASONQUE + zoldonrasib vs GnP; dual endpoints PFS and OS.
PDAC G12D is the most common RAS mutation in PDAC (~40%).
RASONQUE is FDA-approved in US PDAC after prior therapy; safety profile noted.
Zoldonrasib targets G12D; combo aims deeper RAS signaling suppression.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.